Natural Alternatives International Inc

Análisis de la acción Natural Alternatives International Inc (NAII)

$1.110

-0.010 (-0.89%)Al cierre

Loading chart…
Máximo
1.110
Apertura
1.090
Precio medio ponderado por volumen
1.10
Volumen
11.73K
Capitalización
38.26M
Mínimo
1.080
Importe
12.91K
EV/EBITDA, TTM
0.00

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer's preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements.

www.nai-online.com

Análisis de IA of Natural Alternatives International Inc (NAII)

Mantener

Natural Alternatives International Inc is not a good buy right now due to ongoing financial losses and a low RSI of 45.49, indicating potential weakness. The stock has a forward P/E of 13.61, suggesting it may be undervalued, but the significant net loss of $13.54 million in Q4 2026 raises concerns about profitability. The stock is currently trading at $1.11, which is 1.3% of its 52-week range, indicating it is near its low. Investors should be cautious as the company has seen a year-to-date change of -69.08%, reflecting substantial declines in value.

Métricas de valoración

El PER previsto actual de Natural Alternatives International Inc (NAII) es 13.61, frente a su media de 5 años de 2.52.

PER previsto

Sobrevalorado
Media 5A P/E
2.52
P/E actual
13.61
Sobrevalorada
8.16
Infravalorada
-3.11

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para NAII

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%NAII

$3.15

Precio del escenario

B

Base

Base · 50%NAII

$3.11

Precio del escenario

B

Bajista

Bajista · 25%NAII

$2.93

Precio del escenario

Preguntas frecuentes sobre NAII, respondidas por Alphio AI

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. Its primary business activity is to provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer ecommerce channels, and retail stores. It manufactures products in a variety of forms, including capsules, tablets, chewable wafers, and powders to accommodate a variety of its customer's preferences. It also seeks to commercialize its patent and trademarks through the direct distribution and sale of CarnoSyn, SR CarnoSyn, TriBsyn, new contract manufacturing opportunities, and various license, royalty, and similar arrangements. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Natural Alternatives International Inc is not a good buy right now due to ongoing financial losses and a low RSI of 45.49, indicating potential weakness. The stock has a forward P/E of 13.61, suggesting it may be undervalued, but the significant net loss of $13.54 million in Q4 2026 raises concerns about profitability. The stock is currently trading at $1.11, which is 1.3% of its 52-week range, indicating it is near its low. Investors should be cautious as the company has seen a year-to-date change of -69.08%, reflecting substantial declines in value.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar